

ZOGENIX

Zogenix Prices Public Offering of Common Stock

September 16, 2011

SAN DIEGO, Sep 16, 2011 (GlobeNewswire via COMTEX) --

Zogenix, Inc. (Nasdaq:ZGNX) announced today the pricing of its underwritten public offering of 30,000,000 shares of its common stock at \$2.00 per share, before underwriting discounts and commissions. Zogenix has granted the underwriters a 30-day option to purchase up to 4,500,000 additional shares of common stock. All shares of the common stock to be sold in the offering are being offered by Zogenix.

Leerink Swann LLC and Wells Fargo Securities, LLC are acting as joint book-running managers for the offering, and Stifel Nicolaus & Company, Incorporated, William Blair & Company, L.L.C. and Oppenheimer & Co. Inc. are acting as co-managers for the offering.

A registration statement relating to these securities was declared effective by the U.S. Securities and Exchange Commission (SEC) on September 15, 2011. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to their registration or qualification under the securities laws of any such state or other jurisdiction.

This offering is being made only by means of a prospectus, copies of which may be obtained from Leerink Swann LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, Massachusetts 02110, or by calling toll-free 800-808-7525 or emailing a request to Syndicate@Leerink.com and from Wells Fargo Securities, LLC, Attention: Equity Syndicate Department, 375 Park Avenue, New York, New York 10152, or by calling toll-free 800-326-5897 or emailing a request to cmclientsupport@wellsfargo.com.

About Zogenix

Zogenix, Inc. (Nasdaq:ZGNX), with offices in San Diego and Emeryville, California, is a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain. Zogenix's first commercial product, SUMAVEL(R) DosePro(R) (sumatriptan injection) Needle-free Delivery System, was launched in January 2010 for the acute treatment of migraine and cluster headache. Zogenix's lead product candidate, Zohydro(TM) (hydrocodone bitartrate), is a novel, oral, single-entity (without acetaminophen) extended-release capsule formulation currently in Phase 3 clinical trials for the treatment of moderate to severe chronic pain in patients requiring around-the-clock opioid therapy. Zogenix's second DosePro product candidate, Relday(TM), is a proprietary, long-acting injectable formulation of risperidone for the treatment of schizophrenia.

This news release was distributed by GlobeNewswire, www.globenewswire.com

SOURCE: Zogenix

CONTACT: INVESTORS:

Zack Kubow | The Ruth Group
646.536.7020 | zkubow@theruthgroup.com

MEDIA:

Victoria Aguiar | The Ruth Group
646.536.7013 | vaguiar@theruthgroup.com